Both Terpos et al. and Van Oeklen et al. have shown data that ongoing therapy particularly with anti‐CD38 antibodies and BCMA‐targeted therapy significantly reduced antibody responses in myeloma patients.9, 14. Here, TNFRSF17 is linked to plasma cell myeloma.